The Bull Case For Delta Air Lines (DAL) Could Change Following New SIXT Partnership and Earnings Beat - Learn Why

• Delta Air Lines recently reported strong second quarter earnings and announced a new strategic partnership with SIXT USA, enabling SkyMiles members to earn and redeem miles on SIXT rentals booked through Delta’s Cars & Stays platform at over 2,000 locations worldwide.
• This collaboration enhances Delta’s loyalty program and premium travel experience, aligning both brands at major U.S. airports while offering added convenience and travel rewards to customers.
• We'll explore how this partnership, which boosts Delta's SkyMiles value through expanded travel rewards and convenience, influences the company's investment narrative.

Rare earth metals are an input to most high-tech devices, military and defence systems and electric vehicles. The global race is on to secure supply of these critical minerals. Beat the pack to uncover the 25 best rare earth metal stocks of the very few that mine this essential strategic resource.

Delta Air Lines Investment Narrative Recap

To be a Delta Air Lines shareholder today, you need confidence in its ability to capture value from premium travel and loyalty segments while managing industry headwinds like economic uncertainty and margin pressure. The new partnership with SIXT USA meaningfully supports Delta’s SkyMiles platform and premium travel strategy but does not materially alter the biggest short-term catalyst, margin protection amid stagnant domestic and main cabin demand, or reduce the risk tied to economic softness and decreasing capacity.

Among recent announcements, Delta’s Q2 earnings stand out: strong net income growth despite flat revenues signals the continued effectiveness of the premium and loyalty focus that the SIXT partnership amplifies. The link between enhanced loyalty program benefits and resilient earnings will be critical as management looks to protect margin and cash flow going forward.

On the other hand, investors should not overlook the ever-present risk that demand in the core domestic cabin segment could soften further if economic conditions deteriorate or...

Read the full narrative on Delta Air Lines (it's free!)

Delta Air Lines' outlook anticipates $67.9 billion in revenue and $4.7 billion in earnings by 2028. This is based on a 3.1% annual revenue growth rate and a $0.2 billion increase in earnings from the current level of $4.5 billion.

Uncover how Delta Air Lines' forecasts yield a $64.37 fair value, a 15% upside to its current price.

Exploring Other Perspectives

Seven private investors in the Simply Wall St Community estimated Delta’s fair value in a wide US$40.57 to US$86.63 range. While opinions diverge sharply, flat capacity growth and economic uncertainty continue to influence expectations for Delta’s future performance; consider reviewing these varied viewpoints next.

Explore 7 other fair value estimates on Delta Air Lines - why the stock might be worth as much as 55% more than the current price!

Build Your Own Delta Air Lines Narrative

Disagree with existing narratives? Create your own in under 3 minutes - extraordinary investment returns rarely come from following the herd.

• A great starting point for your Delta Air Lines research is our analysis highlighting 2 key rewards and 3 important warning signs that could impact your investment decision.
• Our free Delta Air Lines research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Delta Air Lines' overall financial health at a glance.

Looking For Alternative Opportunities?

Don't miss your shot at the next 10-bagger. Our latest stock picks just dropped:

• The end of cancer? These 25 emerging AI stocks are developing tech that will allow early identification of life changing diseases like cancer and Alzheimer's.
• Trump's oil boom is here - pipelines are primed to profit. Discover the 22 US stocks riding the wave.
• AI is about to change healthcare. These 26 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com